Company Profile For Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States. The Company is divided into two business segments: generic pharmaceuticals and brand pharmaceuticals. The Company is operating the brand pharmaceutical segment under the name Strativa Pharmaceuticals. In the brand segment, Par Pharmaceutical markets brand products under trademarked brand names designed to create an association between the products and their intended uses. In June 2008, the Company entered into an exclusive licensing agreement with MonoSol Rx under which it acquired the commercialization rights in the United States to MonoSol’s thin film formulation of ondansetron.

BRIEF: For the six months ended 27 June 2009, Par Pharmaceutical Companies, Inc.'s revenues totaled $608M. Net income from cont. operation totaled $40.2M vs. a loss of $19.6M. Revenues reflect an increase in income from Generic segment and higher sales from Brand segment. Net income also reflects a decrease in research & development expense, higher gross margin, lower interest expense and presence of gain on bargain purchase.